Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1

Add time:09/04/2019    Source:sciencedirect.com

As part of our ongoing efforts to develop reversible inhibitors of LSD1, we identified a series of 4-(pyrrolidin-3-yl)benzonitrile derivatives that act as successful scaffold-hops of the literature inhibitor GSK-690. The most active compound, 21g, demonstrated a Kd value of 22 nM and a biochemical IC50 of 57 nM. In addition, this compound displayed improved selectivity over the hERG ion channel compared to GSK-690, and no activity against the related enzymes MAO-A and B. In human THP-1 acute myeloid leukaemia cells, 21g was found to increase the expression of the surrogate cellular biomarker CD86. This work further demonstrates the versatility of scaffold-hopping as a method to develop structurally diverse, potent inhibitors of LSD1.

We also recommend Trading Suppliers and Manufacturers of 4-(PYRROLIDIN-1-YL)BENZYLAMINE (cas 114365-04-7). Pls Click Website Link as below: cas 114365-04-7 suppliers

Prev:Identification and synthesis of some contaminants present in 4-methoxyamphetamine (PMA) prepared by the Leuckart method
Next:Short communicationIdentification of a metabolite of atrazine, N-ethyl-6-methoxy-N′-(1-methylethyl)-1,3,5-triazine-2,4-diamine, upon incubation with rat liver microsomes)